<SEC-DOCUMENT>0001157523-19-000729.txt : 20190402
<SEC-HEADER>0001157523-19-000729.hdr.sgml : 20190402
<ACCEPTANCE-DATETIME>20190402161521
ACCESSION NUMBER:		0001157523-19-000729
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20190402
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190402
DATE AS OF CHANGE:		20190402

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			USANA HEALTH SCIENCES INC
		CENTRAL INDEX KEY:			0000896264
		STANDARD INDUSTRIAL CLASSIFICATION:	MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
		IRS NUMBER:				870500306
		STATE OF INCORPORATION:			UT
		FISCAL YEAR END:			1229

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35024
		FILM NUMBER:		19724854

	BUSINESS ADDRESS:	
		STREET 1:		3838 WEST PARKWAY BLVD.
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84120-6336
		BUSINESS PHONE:		8019547100

	MAIL ADDRESS:	
		STREET 1:		3838 WEST PARKWAY BLVD.
		STREET 2:		3838 WEST PARKWAY BLVD.
		CITY:			SALT LAKE CITY
		STATE:			UT
		ZIP:			84120-6336

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	USANA INC
		DATE OF NAME CHANGE:	19930125
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a51963611.htm
<DESCRIPTION>USANA HEALTH SCIENCES, INC. 8-K
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2019 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-size: 10pt; font-family: Times New Roman">
    <p style="text-align: center">
      <br>
      <font style="font-size: 16pt; font-family: Times New Roman"><b>UNITED
      STATES</b></font><font style="font-size: 16pt"><br style="font-size: 16pt"></font><font style="font-size: 16pt"><br style="font-size: 16pt"></font><font style="font-size: 16pt; font-family: Times New Roman"><b>SECURITIES
      AND EXCHANGE COMMISSION</b></font><br><br><font style="font-size: 12pt; font-family: Times New Roman"><b>WASHINGTON,
      D.C. 20549</b></font><br><font style="font-size: 12pt; font-family: Times New Roman">______________</font><br>
    </p>
    <p style="text-align: center">
      <font style="font-size: 16pt; font-family: Times New Roman"><b>FORM 8-K</b></font><br><font style="font-size: 12pt; font-family: Times New Roman">______________</font><br>
    </p>
    <p style="text-align: center">
      <font style="font-size: 12pt; font-family: Times New Roman"><b>CURRENT
      REPORT</b></font><br><br><font style="font-size: 10pt; font-family: Times New Roman">Pursuant
      to Section 13 or 15(d) of</font><br><br>t<font style="font-size: 10pt; font-family: Times New Roman">he
      Securities Exchange Act of 1934</font><br><br><font style="font-size: 10pt; font-family: Times New Roman">Date
      of Report (Date of Earliest Event Reported):</font><br><font style="font-size: 10pt; font-family: Times New Roman">April
      2, 2019</font><br><br><font style="font-size: 18pt"><b>USANA HEALTH
      SCIENCES, INC.</b></font><br><font style="font-size: 10pt; font-family: Times New Roman">(Exact
      name of registrant as specified in its charter)</font><br><br>Utah<br>(State
      or other jurisdiction of incorporation)<br><br>
    </p>
    <div style="text-align:center">
    <table cellspacing="0" style="font-size: 10pt; margin-left:auto;margin-right:auto; width: 100%; font-family: Times New Roman; margin-bottom: 10.0px">
      <tr>
        <td style="text-align: center; white-space: nowrap; padding-right: 0.0px; padding-left: 0.0px; width: 40%" valign="bottom">
          <p style="margin-top: 0px; margin-bottom: 0px">
            001-35024
          </p>
        </td>
        <td style="width: 20%">
          &#160;
        </td>
        <td style="text-align: center; white-space: nowrap; padding-right: 0.0px; padding-left: 0.0px; width: 40%" valign="bottom">
          <p style="margin-top: 0px; margin-bottom: 0px">
            87-0500306
          </p>
        </td>
      </tr>
      <tr>
        <td style="text-align: center; padding-left: 0.0px; width: 40%" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            (Commission File No.)
          </p>
        </td>
        <td style="width: 20%">

        </td>
        <td style="text-align: center; padding-left: 0.0px; width: 40%" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            (IRS Employer Identification
          </p>
        </td>
      </tr>
      <tr>
        <td style="text-align: center; padding-left: 0.0px; width: 40%" valign="bottom">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
        <td style="width: 20%">

        </td>
        <td style="text-align: center; padding-left: 0.0px; width: 40%" valign="bottom">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Number)
          </p>
        </td>
      </tr>
    </table>
    </div>
    <div style="text-align:center">
    <table cellspacing="0" style="font-size: 10pt; margin-left:auto;margin-right:auto; width: 100%; font-family: Times New Roman; margin-bottom: 10.0px">
      <tr>
        <td style="text-align: center; padding-left: 0.0px" valign="bottom">
          <p style="margin-top: 0px; margin-bottom: 0px">
            3838 West Parkway Boulevard<br>Salt Lake City, Utah 84120
          </p>
        </td>
      </tr>
      <tr>
        <td style="text-align: center; padding-left: 0.0px" valign="bottom">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <font style="font-size: 10pt; font-family: Times New Roman">(Address
            of principal executive offices,</font> <font style="font-size: 10pt; font-family: Times New Roman">Zip
            Code)</font>
          </p>
        </td>
      </tr>
      <tr>
        <td style="text-align: center; padding-left: 0.0px" valign="top">
          <p style="font-size: 10pt; font-family: Times New Roman">
            <font style="font-size: 10pt; font-family: Times New Roman">Registrant&#8217;s
            telephone number, including area code: </font><font style="font-size: 10pt">(801)
            954-7100</font>
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p style="text-align: center">
      <br>

    </p>
    <p>
      <font style="font-size: 10pt; font-family: Times New Roman">Check the
      appropriate box below if the Form 8-K filing is intended to
      simultaneously satisfy the filing obligation of the registrant under any
      of the following provisions:</font>
    </p>
    <p>
      <font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font>
      <font style="font-size: 10pt; font-family: Times New Roman">Written
      communications pursuant to Rule 425 under the Securities Act (17 CFR
      230.425)</font>
    </p>
    <p>
      <font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font>
      <font style="font-size: 10pt; font-family: Times New Roman">Soliciting
      material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)</font>
    </p>
    <p>
      <font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font>
      <font style="font-size: 10pt; font-family: Times New Roman">Pre-commencement
      communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
      240.14d-2(b))</font>
    </p>
    <p>
      <font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font>
      <font style="font-size: 10pt; font-family: Times New Roman">Pre-commencement
      communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
      240.13e-4(c))</font>
    </p>
<div style="text-align:left">
    <table cellspacing="0" style="font-size: 10pt; width: 100%; font-family: Times New Roman; margin-bottom: 10.0px">
      <tr>
        <td style="text-align: left; padding-left: 0.0px; width: 2%" valign="top">
          <p style="font-size: 10pt">
            <font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font>
          </p>
        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 98%" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Indicate by check mark whether the registrant is an emerging
            growth company as defined in Rule 405 of the Securities Act of
            1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange
            Act of 1934 (17 CFR &#167;240.12b-2).
          </p>
        </td>
      </tr>
    </table>
    </div>
<div style="text-align:left">
    <table cellspacing="0" style="font-size: 10pt; width: 100%; font-family: Times New Roman; margin-bottom: 10.0px">
      <tr>
        <td style="text-align: left; padding-left: 0.0px; width: 2%" valign="top">
          <p style="font-size: 10pt">
            <font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font>
          </p>
        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 98%" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            If an emerging growth company, indicate by check mark if the
            registrant has elected not to use the extended transition period
            for complying with any new or revised financial accounting
            standards provided pursuant to Section 13(a) of the Exchange Act.
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
    <div style="text-indent: 0pt; margin-left: 0pt; width: 100%; margin-right: 0pt; margin-bottom: 10pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>

    </p>
    <p style="white-space: nowrap">
      <b>Item&#160;2.02 &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Results of Operations and Financial
      Condition.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b>
    </p>
    <p>
      On April 2, 2019, USANA Health Sciences, Inc. (the &#8220;Company&#8221; or &#8220;USANA&#8221;)
      issued a press release announcing its preliminary financial results for
      the first quarter ended March 30, 2019 along with updated outlook for
      the full year 2019.&#160;&#160;A copy of the press release is furnished herewith
      as Exhibit to this Current Report on Form 8-K and is incorporated herein
      by reference.&#160;&#160;This document will be posted on the Company&#8217;s corporate
      website, www.usana.com.
    </p>
    <p>
      The information in this Current Report is being furnished and shall not
      be deemed &#8220;filed&#8221; for the purposes of Section&#160;18 of the Securities
      Exchange Act of 1934, as amended, or otherwise subject to the
      liabilities of that Section. The information in this Current Report
      shall not be incorporated by reference into any registration statement
      or other document pursuant to the Securities Act of 1933, as amended.
      The furnishing of the information in this Current Report is not intended
      to, and does not, constitute a representation that such furnishing is
      required by Regulation FD or that the information this Current Report
      contains is material investor information that is not otherwise publicly
      available.
    </p>
    <p>

    </p>
    <p>
      <b>Item 7.01 &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Regulation FD Disclosure</b>
    </p>
    <p>
      The information disclosed above under Item 2.02, as well as the exhibit
      attached under Item 9.01 below is incorporated herein by reference.
    </p>
    <p>

    </p>
    <p style="white-space: nowrap">
      <b>Item&#160;9.01 &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial Statements and Exhibits. </b>
    </p>
    <p style="white-space: nowrap; margin-left: 90.0px">
      (d)&#160;&#160;Exhibits
    </p>
<div style="text-align:left">
    <table cellspacing="0" style="font-size: 10pt; width: 100%; font-family: Times New Roman; margin-bottom: 10.0px">
      <tr>
        <td style="width: 5%">
          &#160;
        </td>
        <td style="text-align: left; border-bottom-style: solid; border-bottom-width: 1.0pt; padding-left: 0.0px; border-bottom-color: black; width: 13%" valign="bottom">
          <b>Exhibit No.</b>
        </td>
        <td style="width: 2%">
          &#160;
        </td>
        <td style="text-align: left; border-bottom-style: solid; border-bottom-width: 1.0pt; padding-left: 0.0px; border-bottom-color: black; width: 80%" valign="bottom">
          <b>Description</b>
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="text-align: left; white-space: nowrap; padding-right: 0.0px; padding-left: 0.0px; width: 13%" valign="top">
          99.1
        </td>
        <td style="width: 2%">

        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 80%" valign="top">
          Press release issued by USANA Health Sciences, Inc. dated April 2,
          2019 (furnished herewith).
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
    <div style="text-indent: 0pt; margin-left: 0pt; width: 100%; margin-right: 0pt; margin-bottom: 10pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>

    </p>
    <p style="text-align: center">
      <br>
      <font style="font-size: 10pt; font-family: Times New Roman"><b>SIGNATURES</b></font><br>
    </p>
    <p>
      Pursuant to the requirements of the Securities Exchange Act of 1934, the
      registrant has duly caused this report to be signed on its behalf by the
      undersigned hereunto duly authorized.
    </p>
    <p style="text-indent: 30.0px; text-align: justify">

    </p>
<div style="text-align:left">
    <table cellspacing="0" style="font-size: 10pt; width: 100%; font-family: Times New Roman; margin-bottom: 10.0px">
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 52%">

        </td>
        <td colspan="2" style="text-align: left; padding-left: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>USANA HEALTH SCIENCES, INC.</b>
          </p>
        </td>
        <td style="width: 10%">

        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 52%">

        </td>
        <td style="width: 3%">

        </td>
        <td style="width: 30%">

        </td>
        <td style="width: 10%">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 52%">

        </td>
        <td style="width: 3%">

        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 30%" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
        <td style="width: 10%">

        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 52%">

        </td>
        <td style="width: 3%">

        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 30%" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
        <td style="width: 10%">

        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-bottom: 2.0px; padding-left: 0.0px; width: 5%" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
        <td style="text-align: left; padding-bottom: 2.0px; padding-left: 0.0px; width: 52%" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
        <td style="text-align: left; padding-bottom: 2.0px; padding-left: 0.0px; width: 3%" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>By:</b>
          </p>
        </td>
        <td style="text-align: left; border-bottom-style: solid; border-bottom-width: 1.0pt; padding-left: 0.0px; border-bottom-color: black; width: 30%" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            /s/ G. Douglas Hekking
          </p>
        </td>
        <td style="width: 10%">

        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 52%">

        </td>
        <td colspan="3" style="text-align: left; padding-left: 0.0px" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            G. Douglas Hekking, Chief Financial Officer
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 52%">

        </td>
        <td style="width: 3%">

        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 30%" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            &#160;
          </p>
        </td>
        <td style="width: 10%">

        </td>
      </tr>
      <tr>
        <td style="text-align: left; padding-left: 0.0px; width: 5%" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            Date:
          </p>
        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 52%" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            April 2, 2019
          </p>
        </td>
        <td style="width: 3%">

        </td>
        <td style="width: 30%">

        </td>
        <td style="width: 10%">

        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
    <div style="text-indent: 0pt; margin-left: 0pt; width: 100%; margin-right: 0pt; margin-bottom: 10pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>

    </p>
    <p style="text-align: center">
      <b>Exhibit Index</b>
    </p>
<div style="text-align:left">
    <table cellspacing="0" style="font-size: 10pt; width: 100%; font-family: Times New Roman; margin-bottom: 10.0px">
      <tr>
        <td style="width: 5%">
          &#160;
        </td>
        <td style="text-align: left; border-bottom-style: solid; border-bottom-width: 1.0pt; padding-left: 0.0px; border-bottom-color: black; width: 13%" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>Exhibit No.</b>
          </p>
        </td>
        <td style="text-align: left; padding-bottom: 2.0px; padding-left: 0.0px; width: 2%" valign="top">
          &#160;
        </td>
        <td style="text-align: left; border-bottom-style: solid; border-bottom-width: 1.0pt; padding-left: 0.0px; border-bottom-color: black; width: 80%" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>Description</b>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="text-align: left; white-space: nowrap; padding-right: 0.0px; padding-left: 0.0px; width: 13%" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <a href="a51963611ex99_1.htm">99.1</a>
          </p>
        </td>
        <td style="width: 2%">

        </td>
        <td style="text-align: left; padding-left: 0.0px; width: 80%" valign="top">
          <p style="margin-top: 0px; margin-bottom: 0px">
            <a href="a51963611ex99_1.htm">Press release issued by USANA Health
            Sciences, Inc. dated April 2, 2019 (furnished herewith).</a>
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p style="text-align: left">

    </p>
  </body>
</html>
<!--<!DOCTYPE html
     PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN"
     "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">-->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a51963611ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2019 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-size: 8pt; font-family: Times New Roman">
    <p style="text-align: right">
      <b>Exhibit 99.1</b>
    </p>
    <p style="text-align: center">
      <font style="font-size: 12pt; font-family: Times New Roman"><b>USANA
      Health Sciences Provides Preliminary First Quarter Net Sales and Updates
      Fiscal Year 2019 Outlook</b></font>
    </p>
    <p style="text-align: center">

    </p>
    <p>
      SALT LAKE CITY--(BUSINESS WIRE)--April 2, 2019--USANA Health Sciences,
      Inc. (NYSE: USNA) today announced preliminary first quarter net sales
      and updated its outlook for fiscal year 2019. The Company anticipates
      that first quarter 2019 net sales will range between $270 and $273
      million, compared with $292 million in the prior-year period.
    </p>
    <p>
      In conjunction with the Company&#8217;s earnings release and Form 8-K filed on
      February 5, 2019, the Company provided its full-year guidance for fiscal
      year 2019 and, in doing so, disclosed that it anticipated a softer first
      quarter due to limited promotional activity in each of its regions. The
      lack of promotional activity during the quarter, however, had a
      larger-than-expected impact on sales. Additionally, net sales in the
      Company&#8217;s mainland China market were unfavorably impacted by negative
      media coverage of the health product industry and direct selling
      industry in China throughout the quarter in connection with the 100-day
      review<sup>1</sup> of these industries by the Chinese government, as
      disclosed by the Company in its Form 10-K filed with the Securities and
      Exchange Commission on February 26, 2019. These events resulted in
      softer-than-expected sales for the quarter and have reduced the
      likelihood of the Company achieving the high end of its previously
      issued full-year guidance. Consequently, the Company has updated its
      full-year guidance as follows:
    </p>
    <div style="text-indent: 0pt; margin-left: 0pt; width: 100%; margin-right: 0pt; margin-bottom: 10pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
<div style="text-align:left">
    <table cellspacing="0" style="font-size: 8pt; width: 100%; font-family: Times New Roman; margin-bottom: 10.0px">
      <tr>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="text-align: center; border-bottom-style: solid; border-bottom-width: 1.0pt; padding-left: 0.0px; border-bottom-color: black" valign="bottom">
          <b>Q1 2019 Preliminary Results</b>
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="text-align: center; border-bottom-style: solid; border-bottom-width: 1.0pt; padding-left: 0.0px; border-bottom-color: black" valign="bottom">
          <b>Full-Year 2019</b>

          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>Original Guidance Range</b>
          </p>
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="text-align: center; border-bottom-style: solid; border-bottom-width: 1.0pt; padding-left: 0.0px; border-bottom-color: black" valign="bottom">
          <b>Full-Year 2019</b>

          <p style="margin-top: 0px; margin-bottom: 0px">
            <b>Revised Guidance Range</b>
          </p>
        </td>
      </tr>
      <tr>
        <td style="text-align: center; border-bottom-style: solid; border-bottom-width: 1.0pt; padding-left: 0.0px; border-bottom-color: black" valign="bottom">
          Net sales
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="text-align: center; border-bottom-style: solid; border-bottom-width: 1.0pt; padding-left: 0.0px; border-bottom-color: black" valign="bottom">
          $270 - $273 million
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="text-align: center; border-bottom-style: solid; border-bottom-width: 1.0pt; padding-left: 0.0px; border-bottom-color: black" valign="bottom">
          $1.25 - $1.30 billion
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="text-align: center; border-bottom-style: solid; border-bottom-width: 1.0pt; padding-left: 0.0px; border-bottom-color: black" valign="bottom">
          $1.21 - $1.26 billion
        </td>
      </tr>
      <tr>
        <td style="text-align: center; border-bottom-style: solid; border-bottom-width: 1.0pt; padding-left: 0.0px; border-bottom-color: black" valign="bottom">
          EPS - diluted
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="text-align: center; white-space: nowrap; border-bottom-style: solid; padding-right: 0.0px; border-bottom-width: 1.0pt; padding-left: 0.0px; border-bottom-color: black" valign="bottom">
          $0.97 - $1.01
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="text-align: center; white-space: nowrap; border-bottom-style: solid; padding-right: 0.0px; border-bottom-width: 1.0pt; padding-left: 0.0px; border-bottom-color: black" valign="bottom">
          $5.25 - $5.55
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="border-bottom-style: solid; border-bottom-width: 1.0pt; border-bottom-color: black">
          &#160;
        </td>
        <td style="text-align: center; white-space: nowrap; border-bottom-style: solid; padding-right: 0.0px; border-bottom-width: 1.0pt; padding-left: 0.0px; border-bottom-color: black" valign="bottom">
          $5.00 - $5.35
        </td>
      </tr>
    </table>
    </div>
    <p>
      &#8220;We are updating our outlook for 2019 ahead of our regularly scheduled
      earnings release to maintain transparency with investors,&#8221; said Kevin
      Guest, Chief Executive Officer. &#8220;Our operating plan for 2019 originally
      called for increasing promotional activity as the year progressed. The
      lack of promotional activity during the quarter, however, had a more
      significant impact on our world-wide momentum than we originally
      anticipated, particularly during the seasonal slow-down that we
      experience in many of our markets during Chinese New Year. Additionally,
      the Chinese government&#8217;s 100-day review of the health product and direct
      selling industries in China has been accompanied by negative media
      coverage in China. The 100-day review and resulting negative media
      coverage had a more significant impact on first quarter net sales in
      China than we originally anticipated.&#8221;
    </p>
    <p>
      Guest continued, &#8220;We have several incentives and promotions that are set
      to begin during the second quarter. We have also added a few additional
      incentives and promotions during the year that are designed to drive
      growth. Additionally, we expect that the 100-day review will conclude
      during the second quarter, which should allow us to return to a more
      typical operating environment in China. We are confident that these
      initiatives, as well as our plans for the remainder of the year, will
      drive sales growth during 2019, although at a lower growth rate than
      previously estimated.&#8221;
    </p>
    <div style="text-indent: 0pt; margin-left: 0pt; width: 100%; margin-right: 0pt; margin-bottom: 10pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      Final first quarter results will be released after the close of market
      Tuesday, April 30, 2019. The above statements reflect the Company&#8217;s
      preliminary estimates and views on market trends observed in the first
      quarter of 2019 and are based on information available as of the date
      hereof.
    </p>
    <p>
      <b>About USANA</b>
    </p>
    <p>
      USANA develops and manufactures high-quality nutritional supplements,
      healthy foods and personal care products that are sold directly to
      Associates and Preferred Customers throughout the United States, Canada,
      Australia, New Zealand, Hong Kong, China, Japan, Taiwan, South Korea,
      Singapore, Mexico, Malaysia, the Philippines, the Netherlands, the
      United Kingdom, Thailand, France, Belgium, Colombia, Indonesia, Germany,
      Spain, Romania, and Italy. More information on USANA can be found at <u><b>www.usana.com</b></u><b>.</b>
    </p>
    <p>
      <b>Safe Harbor</b>
    </p>
    <p>
      This press release contains forward-looking statements within the
      meaning of Section 27A of the Securities Act and Section 21E of the
      Securities Exchange Act. Our actual results could differ materially from
      those projected in these forward-looking statements, which involve a
      number of risks and uncertainties, including: regulatory risk in China
      associated with the Chinese government&#8217;s 100-day review of the health
      product and direct selling industries; continued negative media coverage
      in China in connection with the Chinese government&#8217;s 100-day review of
      these industries; global economic conditions generally; reliance upon
      our network of independent Associates; risk associated with governmental
      regulation of our products, manufacturing and marketing activities;
      adverse publicity risks globally; risks associated with our
      international expansion and operations; and risks associated with the
      internal investigation into BabyCare&#8217;s operations. The contents of this
      release should be considered in conjunction with the risk factors,
      warnings, and cautionary statements that are contained in our most
      recent filings with the Securities and Exchange Commission. The
      forward-looking statements set forth our beliefs as of the date hereof.
      We do not undertake any obligation to update any forward-looking
      statement after the date hereof, except as required by law.
    </p>
    <div style="text-indent: 0pt; margin-left: 0pt; width: 100%; margin-right: 0pt; margin-bottom: 10pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      <sup>1</sup> In January 2019, following unfavorable media coverage of
      certain health product companies and direct selling companies, several
      departments of the Chinese government initiated a 100-day review of
      health product and direct selling companies in China. This 100-day
      review requires direct-selling companies to conduct a self-assessment of
      the regulatory compliance of their business and to provide information
      to the government regarding the same. The 100-day review will also
      entail a review of a company's regulatory compliance by various
      departments of the Chinese government. During this review period, the
      Chinese government has, among other things, (i) instructed direct
      selling companies to not hold large distributor meetings, and (ii)
      suspended its application review process for direct sales licenses and
      authorizations.
    </p>
    <p>
      CONTACT:<br>Investors contact:<br>Patrique Richards<br>Investor Relations<br>(801)
      954-7961<br><u>investor.relations@us.usana.com</u>
    </p>
    <p>
      Media contact:<br>Dan Macuga<br>Public Relations<br>(801) 954-7280
    </p>
    <p style="white-space: nowrap">

    </p>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
